

Bod Australia Limited (ASX:BDA) is a developer, distributor and marketer of health products and supplements, with a focus on plant-based extracts including medicinal cannabis.

#### CAPITAL STRUCTURE

ASX code	BDA
Shares on issue	69.4m
Market Capitalisation	~\$17.7m

#### BOARD & MANAGEMENT

Mr George Livery  
Executive Chairman

Ms Jo Patterson  
Chief Executive Officer

Mr Stephen Thompson  
Executive Director

Mr Simon O'Loughlin  
Non-Executive Director

Mr Simon Taylor  
Non-Executive Director

Mr Stephen Kelly  
Company Secretary

#### CONTACT

Level 1, 377 New South Head Rd  
Double Bay, NSW 2028

T +612 9199 5018

E info@bodaustralia.com.au

## Distribution agreement to bolster medicinal cannabis sales in Australia and New Zealand

- **Agreement with leading medical cannabis distributor Burleigh Heads Cannabis (BHC) for MediCabilis™**
- **Provides Bod with access to Burleigh Heads Cannabis wholesale network and partner company, Cannabis Doctors Australia (CDA)**
- **CDA provide education, support and products to patients and physicians seeking access to medicinal cannabis in Australia**
- **CDA has a number of established clinics and a large and expanding client base in Australia – Responsible for over 1,800 medicinal cannabis prescriptions since October 2018**
- **Patient approvals underway with orders expected near term – Bod anticipates prescription volumes to increase in the coming months**
- **Premium quality and consistent nature of MediCabilis™ positions Bod favourably to meet growing demand**

**Sydney, Australia – 21 June 2019:** Cannabis focused healthcare company, Bod Australia Limited (“Bod”, the “Company”) (ASX: BDA) has secured a distribution agreement with Burleigh Heads Cannabis (BHC) and partner company, Cannabis Doctors Australia (CDA) for its pharmaceutical grade medicinal cannabis product, MediCabilis™ 5% CBD ECs315 (MediCabilis™).

BHC is a leading Australian distributor and supplier of medicinal cannabis products. BHC is dedicated to providing premium natural cannabinoid medicines for the benefit of the community.

Under the agreement, Bod will gain access to BHC’s wholesale network and partner company, Cannabis Doctors Australia. CDA provides education, support and products to patients and doctors seeking access to medicinal cannabis in Australia.

CDA a number of clinics and an established patient base throughout Australia. Since October 2018, CDA have successfully processed over 1,300 Special Access Scheme Category B approvals, resulting in more than 1,800 medicinal cannabis prescriptions. The Group is also expanding into New Zealand in the near term.

CDA has commenced patient approvals for MediCabilis™ through its physical clinics and telehealth service. Bod anticipates strong demand from patients with prescriptions to increase over the coming months. These sales will have the potential to underpin revenue growth for Bod Australia.

The consistency, premium quality, reliability and safety data associated with MediCabilis™ were instrumental in securing the agreement. Bod is now well placed to meet the growing demands of patients that are seeking premium quality, safe and consistent medicinal cannabis products.

Bod will also access CDA’s extensive network of medical specialists and physicians through its Medicinal Cannabis Education Program, which gives patients greater access to Bod’s superior range of clinically trialled products.

Further, Bod and BHC intend to collaborate to produce novel non-THC cannabis prescription products to meet growing physician and patient needs.

**Bod Australia CEO Jo Patterson said:** "Burleigh Heads Cannabis and Cannabis Doctors Australia are leaders in medicinal cannabis and have extensive networks of medical specialists, physicians and patients nationwide. This provides an excellent foundation for Bod to grow medicinal cannabis sales much more rapidly in Australia and New Zealand in the coming months.

"As well, Bod is in ongoing discussions with a number of potential distribution partners internationally to drive further revenue growth and looks forward to updating shareholders in the near term."

**Guy Headley, Director of Operations of CDA Health, (BHC's parent company), added:** "We are thrilled to be working with Bod. The premium quality of MediCabilis™ 5% CBD ECs315 supported by its Phase I clinical Research and Bod's firm commitment to reliability aligns with the CDA group's core values and has been critical in this agreement. Australian and New Zealand patients are set to benefit from another strong product offering through this solid partnership."

– ENDS –

## ABOUT BOD AUSTRALIA

**Bod Australia Limited (ASX:BDA)** is a developer, distributor and marketer of health and skincare products. Bod works with plant based extracts, with specific expertise in leveraging the health benefits associated with cannabis and hemp.

Bod is rapidly building an integrated cannabis business, underpinned by agreements with international counterparties Linnea SA, a leading Swiss botanicals extracts manufacturer and iX Biopharma Limited, a late stage Singapore-listed pharmaceutical company. Bod is actively developing a range of over-the-counter and prescription products based on its unique, standardised, pharmaceutical grade cannabis extracts.

The Company has a large distribution footprint in Australia, selling prescription and OTC products to over 1,000 retail outlets, including pharmacies, retail stores and healthcare chains. The Company also has distribution agreements with two of Australia's largest pharmacy wholesalers providing it with access to over two thirds of the market. Bod is also actively building capability in key European markets that it witnesses near term growth prospects.

[BODAUSTRALIA.COM](http://BODAUSTRALIA.COM)

### About Burleigh Heads Cannabis:

Burleigh Heads Cannabis is a leading Australian Medical Cannabis distributor whom are dedicated to providing quality solutions in the field of natural cannabinoid medicine for the benefit of the community. BHC's mission is focused on providing easily accessible and quality products and services to those in need. BHC has a team of compassionate experts in the field of cannabinoid science driven to provide affordable time-tested medicine to the people.

### About Cannabis Doctors Australia:

Cannabis Doctors Australia provides education, support and products to patients and doctors looking to access Medicinal Cannabis in Australia. CDA assists doctors and patients to navigate the process of applying, prescribing and sourcing medical cannabis legally. CDA provides simple to follow educational resources and one-to-one service from through their consultant doctors free of charge.

### For more information please contact:

Jo Patterson  
Chief Executive Officer  
[info@bodaustralia.com](mailto:info@bodaustralia.com)  
+61 2 9199 5018

Henry Jordan  
Six Degrees Investor Relations  
[henry.jordan@sdir.com.au](mailto:henry.jordan@sdir.com.au)  
+61 431 271 538